MyMD Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
MyMD Pharmaceuticals has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually.
Key information
6.8%
Earnings growth rate
16.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -31.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully
Sep 01
We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate
May 19MyMD Pharma receives grant from European patent office for Supera-CBD compound
Aug 30Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Jul 08Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky
Apr 12MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans
Aug 29Revenue & Expenses BreakdownBeta
How MyMD Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -8 | 8 | 8 |
| 30 Sep 23 | 0 | -7 | 8 | 7 |
| 30 Jun 23 | 0 | -14 | 8 | 7 |
| 31 Mar 23 | 0 | -13 | 6 | 7 |
| 31 Dec 22 | 0 | -15 | 6 | 9 |
| 30 Sep 22 | 0 | -15 | 7 | 7 |
| 30 Jun 22 | 0 | -16 | 7 | 9 |
| 31 Mar 22 | 0 | -31 | 22 | 8 |
| 31 Dec 21 | 0 | -30 | 21 | 7 |
| 30 Sep 21 | 0 | -31 | 22 | 7 |
| 30 Jun 21 | 0 | -29 | 22 | 5 |
| 31 Mar 21 | 0 | -12 | 6 | 4 |
| 31 Dec 20 | 0 | -9 | 6 | 2 |
| 31 Dec 19 | 0 | -10 | 6 | 4 |
Quality Earnings: MYMD is currently unprofitable.
Growing Profit Margin: MYMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MYMD is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare MYMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: MYMD has a negative Return on Equity (-31.31%), as it is currently unprofitable.